Sierra Science has done a lot of work in this field and I appreciate and support Bill Andrews’ expertise in this area. He is the authority on the matter of telomerase. Werner syndrome and Progeria are both accelerated aging diseases and are marked by short telomeres.
BioViva will not take telomere lengthening therapies off our top-ten anti-aging list until therapies have been tried in-vivo at the level needed to lengthen the telomeres to full length and the data collected. Animals studies point to no and even reduced risk of cancer. I believe this follow through method needs to be instated with all potential therapies before they are moved aside. We can not move forward on hypothetical reasoning. Human data is greatly needed. Best,Elizabeth Parrish
Liz,L.Parrish – Skype
On Dec 30, 2014, at 12:51 PM, email@example.com wrote:The earlier Mouse study paper is here:http://m.embomolmed.embopress.org/content/4/8/691Appreciate increasing telomere length is not the only aspect of aging but it’s certainly a key factor and short telomeres lead to a host of problems. I understand from the vector they used applying this to humans would not be difficult.Another consideration is that mice are not the best model as they are not as focused on telomere attrition as we are and have longer telomeres. It could be possible that any benefits may be considerably increased in a Human.There has been considerable debate that it causes cancer though from my research recently it appears that telomeres of optimal length protect against it, whereas short telomeres encourage it. I’m not an expert of course but it does seem telomere rejuvenation is a worthwhile avenue.